



Lung Cancer Europe

2024 IMPACT REPORT



MESSAGE FROM OUR PRESIDENT

2024 was a year of growth and laying strong foundations for Lung Cancer Europe.

As Vice President last year, I saw first-hand how much our community achieved together: a landmark 9th LuCE Report with over 2,000 voices represented, the launch of our Access to Treatment Atlas, and the reach of our Get Checked! campaign across Europe. We also strengthened our presence in EU projects and major conferences, ensuring the perspectives of people affected by lung cancer are heard where it matters most.

Because of this work, we were able to move into 2025 ready to grow. LuCE is blossoming, our membership is expanding, our voice is being recognised, and our influence is increasing. Thank you to every member, partner and supporter who made 2024 such a vital year.

Debra Montague, President, LuCE


OUR 2024 HIGHLIGHTS

9th LuCE Report

2,040

participants
(1,432 people with lung cancer, **608** caregivers) from **34** countries.

Available in **20** languages / **21** national versions.



Access to Treatment Atlas launched

First pan-European tool mapping access to lung cancer treatments in **30 countries**.



Get Checked! "Get Educated" Campaign

72,800

organic impressions across LuCE channels.
Endorsed by ECO, ERS, ELF and Lungs Europe.



Scientific leadership

Abstract on knowledge and shared decision-making selected for oral presentation at **WCLC 2025**.

LuCE also contributed to **ELCC, WCLC San Diego, ERS** and **ESMO**.

Policy and advocacy

Represented the **lung cancer voice** at the **EMA's PCWP/HCPWP** meeting.

Wrote to the European Parliament calling for urgent action on lung cancer.



European Parliament

EU projects

6 active EU projects with LuCE involvement:



3LUNG



IDERHA
integrating health data

GUDEMARD



SPACETIME
Spatially Decoding Lung Cancer



INSPIRE



SOLACE

11 LuCE members serving on EU project advisory boards, representing **9 different countries**.

LuCE has strengthened its role as the patient voice in key innovation areas: health data, AI in healthcare, liquid biopsy, spatial biomarkers, lung cancer screening and gene therapy.

In 2024, LuCE contributed patient perspectives at the **EPF panel** and **IDERHA Public Forum**.

Community growth

10 new member organisations joined in 2024.

28 member representatives from **18 countries** came together at our Madrid Members Meeting.

Communications

Increased social media followers across all channels in 2024.

7 new YouTube videos released for **Lung Cancer Awareness Month**.

LOOKING AHEAD

Thanks to these achievements, LuCE is now in a strong position to grow, lead, and keep the voice of people affected by lung cancer at the heart of European health policy.



Our LuCE membership reinforces one powerful message: collaboration across Europe is essential as we jointly fight lung cancer. Working together, we can drive bigger, faster, and more meaningful change for our community.

Soumitra Böse, Treasurer,
EGFR+ UK



Collaboration is key to progress in lung cancer advocacy. It's exciting to connect with the incredible LuCE community, share insights, and work together to drive better outcomes for all.

Yvonne Diaz, Co-founder & Chair,
Oncogene Cancer Research



I look forward to the joint learning in LuCE workshops and the always inspiring exchange with patient advocates from all over Europe.

Nicoline Ehrhardt, Chair,
ALK Positive Europe



Lung Cancer Europe

www.lungcancereurope.eu